



HARMONY

Healthcare Alliance for Resourceful Medicines
Offensive against Neoplasms in Hematology

Big data for blood cancer: HARMONY can accelerate your research to benefit patients with Hematologic Malignancies.

Find out how! →

The HARMONY Alliance uses big data analytics to accelerate the development of personalized treatments for patients with Hematologic Malignancies. HARMONY is a unique partnership of more than 80 public, private and patient organizations, funded by the Innovative Medicines Initiative.

HARMONY researchers are already mining the unique HARMONY Big Data Platform to address pressing research questions in ALL, AML, CLL, MDS, NHL, MM, and pediatric HMs. Please join us in this large European endeavor to improve the care for blood cancer patients.

→ **Attend the HARMONY Session**
Saturday, 15 June 2019 | Hall E106 | 14:45-16:15 hrs.

→ **Join the HARMONY Partnering Meeting**
Saturday, 15 June 2019 | Room D201 | 16:15-17:45 hrs.

→ **Visit the HARMONY booth in the EHA
Collaboration Plaza at the exhibition.**

Did we trigger your interest? Let's connect!

We look forward to presenting our ongoing research projects, explaining how data quality, safety, and privacy are ensured, and showing that we are developing core outcome sets. More importantly, we would like to discuss how your research may benefit from HARMONY and how you can contribute. We are eager to welcome you as a new Associated Member of our network!

#bigdataforbloodcancer

Big Data to Enable Better and Faster Treatments for Patients with Hematologic Malignancies

The HARMONY Alliance:

European Network of Excellence for Big Data in Hematology: currently 53 Partners and 35 Associated Members from 22 European countries.

A public-private partnership funded by the Innovative Medicines Initiative. 2017-2021.



The HARMONY Big Data Platform:

Captures 45,000 data records from European blood cancer patients in 2019 and will expand to 100,000 sets by 2021. Includes diagnostics, genomics, treatment choices, and outcomes collected by Partners and Associated Members. Focus on ALL, AML, CLL, MDS, MM, NHL and Pediatric HM.

The HARMONY Anonymization Concept:

Ensures that the intended import of data, as well as the subsequent use of such data as envisaged by HARMONY, comply with ethical guidelines and all applicable EU data protection laws (GDPR), without impacting the clinical value of the relevant data.

www.harmony-alliance.eu



#bigdataforbloodcancer



HARMONY Alliance is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

Algorithms to transform knowledge into better medicine outcomes

HARMONY focus - 7 HMs: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies.

www.harmony-alliance.eu/en/research-projects

Check out our current projects, more to follow.

How do genetic abnormalities in ALL cells correlate to prognosis and treatment response?

How do gene-gene interactions influence treatment outcomes in AML patients?

What are the most important outcomes for AML, according to patients, clinicians, health authorities, and the pharmaceutical industry?

What is the best way to prevent and manage complications of APL treatment?

How do mutations in 11 of the most frequently mutated genes in CLL correlate to prognosis and treatment response?

Which subgroups of MDS patients benefit from treatment with hypomethylating agents?

Does one specific treatment provide improved outcomes in patients with aggressive MM?

What are the molecular and genetic drivers of T-cell Non-Hodgkin Lymphomas?

PARTNERS: Abbvie, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) | Amgen | Assistance Publique–Hôpitaux de Paris (AP-HP) | Barts Health NHS Trust | Bayer AG | BfArM Bundesinstitut für Arzneimittel und Medizinprodukte | Celgene | Charité – Universitätsmedizin | Berlin | EAPM (European Alliance for Personalised Medicine) | ELN Foundation | EORTC (European Organisation for Research and Treatment of Cancer) | Erasmus MC Cancer Institute Rotterdam | ERIC European Research Initiative on CLL | European Group for Blood and Marrow Transplantation | European Hematology Association (EHA) | FisMonlus Fondazione Italiana Sindromi | Flanders Institute of Biotechnology (VIB) | Genome Research Limited (GRL-SANGER) | German Society of Pediatric Onco-hema (GPOH) | GMV Soluciones Globales | Internet S.A.U. | Goethe University Frankfurt (GUF) | GRAALL Group for Research on Adult ALL | Groupe Francophone des Myelodysplasies (GFM) | Heinrich-Heine-universität-Düsseldorf | Hospital Universitario La Fe de la Comunidad Valenciana (HULAFE) | IBSAL | IJC Josep | Carreras Leukaemia Research Institute | Janssen | LeukaNET Patient Advocacy Group | LMU Ludwig Maximilians Universität München | Lymphoma Scientific Association (LYSA) | Masarykova Univerzita | MediSapiens | Medizinische Universität Wien | Menarini Ricerche | Munich Leukemia Laboratory GmbH (MLL) | NICE (National Institute for Health and Care Excellence) | Novartis | OPBG & AIEOP (Associazione Italiana di Ematologia e Oncologia Pediatrica) | SYNAPSE Research Management Partners | Takeda | UNAV Universidad de Navarra | UNIBO Alma Mater Studiorum – Università di Bologna | UNITO Università degli studi di Torino | Universität Ulm | University Hospital Vall d'Hebron | University of Cambridge | University of Helsinki | University of Newcastle upon Tyne | University of Rome Tor Vergata | University of York | VU University Medical Center

PATIENT CLUSTER: Acute Leukemia Advocates Network (ALAN) | Childhood Cancer International (CCI) | CLL Advocates Network | LeukaNET Patient Advocacy Group | Lymphoma Coalition | MDS Foundation | Myeloma Patients Europe

ASSOCIATED MEMBERS: Aghia Sophia Hospital | ALFA Group | Azienda Ospedaliero Universitaria di Ferrara | Carol Davila University of Medicine and Pharmacy | CZECH Leukemia Study Group | European Myeloma Network | FICUS | Fondazione GIMEMA | Fondazione IRCCS Ca'Granda Orpedale Maggior Policlinico | GELTAMO (Grupo Español de linfomas y trasplantes de médula ósea) | GESMD (Grupo Español de Síndromes Mielodisplásicas) | Hospital 12 de Octubre | Hospital del Mar | HOVON (Haemato Oncology Foundation for Adults in the Netherlands) | INAB/CERTH (Institute of Applied Biosciences at the Center for Research and Technology Hellas) | Instituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST IRCCS) | Israeli Society of Hematology and Blood Transfusion | Karoliska Institute | Medical University of Lublin | Oncotryol (Center for Personalized Cancer Medicine) | PETHEMA | Queen University of Belfast | Rigshospitalet | Royal Bournemouth | Spanish CETLAM Cooperative Group | The Fondazione Italiana Linfomi ONLUS | Università degli studi di Bari | Aldo Moro | Universitätsklinikum Essen | University Hospital Carl Gustav Carus Dresden | University of Eastern Piedmont and Oncology Institute of Oncology Institute of Southern Switzerland | University of Milano-Bicocca | University of Munich | University of Pisa | University of Southampton | Università Vita Salute San Raffaele.